Introduction {#s1}
============

The incidence of diabetes has significantly increased during the last three decades, and in 2010, there were an estimated 21 million people with diagnosed diabetes in the U.S. ([@B1],[@B2]). People with prediabetes and diabetes have a substantially elevated risk for cardiovascular disease (CVD), and approximately half of individuals aged older than 65 years with diabetes have experienced a CVD event ([@B3],[@B4]). Prediabetes is a precursor of diabetes, and blood glucose---whether measured by fasting glucose, glycated hemoglobin, or 2-h postprandial glucose---is one of the most important predictors of subsequent diabetes ([@B4],[@B5]). However, only ∼2% of individuals with prediabetes progress to diabetes per year, and exposure to hyperglycemia via its damage to the vasculature may contribute to subclinical myocardial damage along with the damaging effects of traditional CVD risk factors ([@B6],[@B7]).

As a result of the strong association between diabetes and CVD, the 2013 atherosclerotic cardiovascular disease (ASCVD) lipid treatment guidelines identify patients with diabetes as one of the four groups to benefit from statin treatment ([@B8]). High-sensitivity cardiac troponin T (hs-cTnT) is a marker of subclinical myocardial damage that has been proposed for use in the risk stratification of asymptomatic individuals ([@B9]--[@B11]). People with diabetes have significantly higher hs-cTnT values than those without diabetes, although an increased risk of incident CVD is observed in individuals with and without diabetes with elevated hs-cTnT ([@B12]).

hs-cTnT may incorporate an important overlap between diabetes and CVD because the subclinical cardiac microvascular damage reflected by an elevated hs-cTnT may be at least partially secondary to hyperglycemia, even in the prediabetic range, along with other CVD risk factors ([@B13]). A better understanding of which individuals are most likely to progress to overt diabetes may highlight possible pathophysiologic mechanisms for future treatment strategies and help to focus resources on those at highest risk. Therefore, in this analysis, we examined the relationship between hs-cTnT and incident diagnosed diabetes to determine whether the measurement of hs-cTnT may identify individuals who are at high risk for both diagnosed diabetes and the major cardiovascular complications associated with it.

Research Design and Methods {#s2}
===========================

Study Populations {#s3}
-----------------

We included Atherosclerosis Risk in Communities (ARIC) study participants who had hs-cTnT measured at the fourth ARIC examination (Visit 4), which took place from 1996 to 1998 (baseline for this analysis). The ARIC study design has been described in detail previously ([@B14]). Participants were excluded if they had a history of self-reported diabetes or diabetes medication use (*n* = 1,365); had a history of coronary heart disease, stroke, or heart failure (*n* = 1,122); were missing data on incidence of diabetes (*n* = 135); had fasted for \<8 h before the laboratory draw (*n* = 233); did not have available hs-cTnT values (*n* = 195); were missing other important covariates (*n* = 158); or were nonblack or nonwhite (*n* = 24). A total of 8,153 participants met the inclusion criteria, and follow-up was assessed through April 2012.

Data Collection {#s4}
---------------

Standardized questionnaires were used to collect demographic information and other patient-reported data. Height, weight, and blood pressure were measured using standardized protocols during the ARIC Visit 4 examination. Hypertension was defined as a systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or use of a blood pressure--lowering medication. Hypercholesterolemia was defined as patient-reported hypercholesterolemia. Smoking was categorized into never, former, and current groups. Alcohol consumption was categorized into current and not current. Metabolic syndrome was defined as the presence of three or more of the following risk factors: *1*) waist circumference ≥40 inches for men or ≥35 inches for women, *2*) fasting triglycerides ≥150 mg/dL, *3*) HDL cholesterol (HDL-C) \<40 mg/dL for men or \<50 mg/dL for women, *4*) blood pressure ≥130/85 mmHg or treatment for hypertension, and *5*) fasting glucose ≥100 mg/dL. Fasting plasma glucose, plasma total cholesterol, LDL cholesterol (LDL-C), triglycerides, and HDL-C were measured in a centralized laboratory.

Measurement of hs-cTnT {#s5}
----------------------

hs-cTnT was measured in plasma samples, which were centrally stored at −80°C, using a novel precommercial highly sensitive assay (Elecsys Troponin T; Roche Diagnostics, Indianapolis, IN) that can detect troponin levels as low as 3 ng/L. The hs-cTnT assay had a reliability coefficient (*R*) of 0.98, based on 418 blinded replicate samples and a between-assay coefficient of variation of 6.9% for control samples that had a mean hs-cTnT concentration of 29 ng/L ([@B15]). Participants with subclinical myocardial damage were categorized as those with detectable hs-cTnT (≥5 ng/L) at baseline.

Incident Diabetes {#s6}
-----------------

Incident cases of diagnosed diabetes were identified during annual follow-up telephone calls to all participants and defined by participant self-report of diagnosed diabetes or new use of a diabetes medication with follow-up until April 2012. Although the participants were not specifically asked whether they were diagnosed with type 1 or type 2 diabetes, all cases were presumed to be type 2 diabetes based on patient demographics.

Statistical Analyses {#s7}
--------------------

We used Cox proportional hazards models and the Kaplan-Meier survival analysis method to examine the association between baseline hs-cTnT and risk of incident diagnosed diabetes after adjustment for traditional risk factors. We selected these risk factors because of their strong and well-established relationship with diabetes in the literature. In our Cox models, the proportional hazards assumption was not violated based on Schoenfeld residual testing ([@B16]). Model 1 was adjusted for age, race-center, and sex. Model 2 was additionally adjusted for total cholesterol, LDL-C, HDL-C, triglycerides, cholesterol-lowering medication use, BMI, systolic blood pressure, blood pressure--lowering medication use, smoking status, and estimated glomerular filtration rate (eGFR). Model 3 was adjusted for the variables in model 2 plus fasting glucose.

In the Cox proportional hazards models, baseline hs-cTnT was categorized into four groups using cut points consistent with previously reported analyses: ≤5 ng/L, 6--8 ng/L, 9--13 ng/L, and ≥14 ng/L ([@B10],[@B15]). Individuals with hs-cTnT values ≤5 ng/L, where there is reduced precision in measurement, were categorized as the lowest group, and individuals with values ≥14 ng/L, which is approximately the 90th percentile of the ARIC cohort and the 99th percentile specified by the manufacturer, were categorized as the highest group. The cut points of 6--8 ng/L and 9--13 mg/L were used for the remaining two middle groups. To further examine the additional information provided by hs-cTnT beyond traditional risk factors (age, race-center, sex, total cholesterol, HDL-C, LDL-C, triglycerides, BMI, eGFR, systolic blood pressure, blood pressure--lowering medication use, smoking status, cholesterol-lowering medication use, family history of coronary heart disease, waist circumference, physical activity, education level, and annual family income level), we used the Harrell C statistic from Cox proportional hazards models and full follow-up data in progressively adjusted models to examine the additive predictive value of hs-cTnT. We also calculated the continuous net reclassification index (NRI) based on the proportion of subjects with movement in the correct direction upward or downward, averaged for event and nonevent subjects ([@B17]).

We defined a group at low risk for incident diagnosed diabetes as those without hypertension, hypercholesterolemia, or metabolic syndrome. Participants with undiagnosed diabetes were defined as those without self-reported diabetes but with a fasting blood glucose of ≥126 mg/dL at baseline. We examined associations in subjects with and without undiagnosed diabetes to understand whether the magnitude of the association was similar in these subgroups. This is particularly important, because those individuals with elevated baseline glucose (undiagnosed diabetes) would be more likely to be diagnosed with diabetes during early follow-up compared with people without hyperglycemia at baseline.

In addition, to assess a nonlinear association between hs-cTnT and the incidence of diagnosed diabetes, we used two adjusted Cox models with linear splines: one with a single knot at the mean value of 6 ng/L and one with three knots, at 5, 8, and 14 ng/L, which are the values used to define the hs-cTnT groups in this analysis. Participants with an hs-cTnT ≤5 ng/L were used as the comparison group, and individuals with an hs-cTnT \<3 ng/L were assigned a value of 1.5 ng/L, which is halfway between zero and the lower limit of detection ([@B18]). In these analyses, we truncated hs-cTnT values \>99th percentile (25 ng/L).

We evaluated heterogeneity in the association between hs-cTnT and incidence of diagnosed diabetes across prespecified subgroups: *1*) participants with or without traditional risk factors and *2*) participants with an overall low risk of incident diabetes, defined as those without hypertension, hypercholesterolemia, or metabolic syndrome. To examine whether reverse causation influenced our results, we performed a sensitivity analysis censoring the first 2 years and first 5 years of follow-up.

Results {#s8}
=======

Overall, the mean age of participants was 62.5 years (SD 5.6; range 53--75), and 58.9% were female. Participants with higher levels of hs-cTnT were more likely to be male, older, with a higher fasting glucose, BMI, prevalence of hypertension, prevalence of metabolic syndrome, and prevalence of impaired fasting glucose compared with participants with a lower hs-cTnT ([Table 1](#T1){ref-type="table"}). In addition, they were more likely to have lower HDL-C, eGFR, and LDL-C and more likely to be treated with statin therapy.

###### 

Characteristics of participants stratified by hs-cTnT group

                                                   Overall          ≤5 ng/L        6--8 ng/L        9--13 ng/L         ≥14 ng/L            
  ------------------------------------------------ ---------------- -------------- ---------------- ------------------ ------------------- ---------
  hs-cTnT (ng/L)[\*](#t1n1){ref-type="table-fn"}   4.0 (1.5--7.0)   1.5 (1.5--4)   7.0 (6.0--8.0)   10.0 (9.0--11.0)   18.0 (15.0--22.0)   
  Female                                           58.9             71.4           44.8             33.2               23.0                \<0.001
  Black                                            19.2             18.5           19.6             20.4               22.5                0.019
  Age (years)                                      62.5 (5.6)       61.3 (5.3)     63.6 (5.6)       65.1 (5.5)         65.3 (5.6)          \<0.001
  Current drinker                                  34.7             34.5           35.0             36.4               33.2                0.610
  Blood pressure (mmHg)                                                                                                                    
   Systolic                                        126.2 (18.4)     124.5 (17.8)   127.3 (18.2)     130.9 (19.8)       131.4 (19.8)        \<0.001
   Diastolic                                       71.2 (10.0)      70.8 (9.8)     71.6 (9.9)       72.2 (10.7)        72.3 (11.3)         \<0.001
  Hypertension medication                          45.1             40.2           48.4             55.7               64.5                \<0.001
  Cholesterol (mg/dL)                                                                                                                      
   Total                                           202.3 (35.7)     204.8 (35.2)   199.4 (35.9)     197.8 (36.4)       193.7 (36.1)        \<0001
   LDL-C                                           123.9 (33.1)     124.6 (33.3)   123.4 (32.5)     123.3 (33.4)       120.1 (32.3)        0.008
   HDL-C                                           50.3 (15.5)      54.1 (15.5)    50.3 (15.5)      46.4 (15.5)        46.4 (15.5)         \<0.001
  Triglycerides (mg/dL)                            133.2 (64.9)     133.4 (64.2)   131.7 (65.7)     134.1 (64.6)       135.1 (69.2)        0.846
  Hypercholesterolemia                             10.3             10.2           9.9              11.7               9.8                 0.590
  Statin use                                       7.9              7.9            7.3              8.8                8.6                 0.414
  Fasting glucose (mg/dL)                          101.7 (19.1)     100.3 (17.5)   103.2 (20.9)     104.1 (20.3)       106.5 (24.4)        \<0.001
  Impaired fasting glucose                         40.5             36.9           44.9             49.6               45.2                \<0.001
  Undiagnosed diabetes                             5.0              4.0            5.6              6.1                11.6                \<0.001
  Family history diabetes                          24.0             23.6           24.3             26.4               23.4                0.236
  Metabolic syndrome                               40.8             38.2           42.7             47.5               48.9                \<0.001
  BMI (kg/m^2^)                                    28.3 (5.3)       27.9 (5.3)     28.7 (5.5)       29.0 (5.3)         29.4 (5.3)          \<0.001
  eGFR (mL/min/1.73 m^2^)                          86.7 (14.8)      88.6 (14.0)    85.0 (14.7)      82.6 (15.2)        79.7 (18.4)         \<0.001

Continuous variables are presented as mean (SD); categorical variables are presented as percent.

\*Median and interquartile range (25th percentile, 75th percentile).

At baseline, 40.5% of participants had impaired fasting glucose, and 5.0% had undiagnosed diabetes. Over a median follow-up of 13 years, 1,830 participants developed diagnosed diabetes. Unadjusted Kaplan-Meier curves showed a higher risk of incident diagnosed diabetes with increasing hs-cTnT categories and a consistent separation in risk among hs-cTnT groups over time (*P* \< 0.001) ([Fig. 1](#F1){ref-type="fig"}). In multivariable adjusted Cox models, participants in the highest hs-cTnT groups were more likely to report a subsequent diagnosis of diabetes than those with hs-cTnT ≤5 ng/L, with a hazard ratio (HR) of 1.14 (95% CI 0.99--1.33) for the hs-cTnT 9--13 ng/L group and an HR of 1.25 (95% CI 1.03--1.53) for the hs-cTnT group ≥14 ng/L (*P* = 0.018 for trend) ([Table 2](#T2){ref-type="table"}). After further adjustment for fasting glucose, the association was attenuated and no longer statistically significant for these groups, with an HR of 1.12 (95% CI 0.96--1.30) for 9--13 ng/L and an HR of 1.13 (95% CI 0.93--1.38) for ≥14 ng/L. The association between hs-cTnT groups and incident diagnosed diabetes for participants with undiagnosed diabetes at baseline was not significant. Among participants with hs-cTnT ≥14 ng/L, but without undiagnosed diabetes and/or metabolic syndrome, there was a consistently higher risk for incident diagnosed self-reported diabetes compared with those with hs-cTnT ≤5 ng/L, with HRs of 1.82 (95% CI 1.22--2.71) and 1.47 (95% CI 1.05--2.05), respectively, even after adjustment for fasting glucose. There was no significant association for the groups by BMI except for obese (BMI 25--30 kg/m^2^) participants in the highest hs-cTnT group, who had an HR of 1.46 (95% CI 1.04--2.05).

![Kaplan-Meier estimates of the incidence of diabetes stratified by hs-cTnT group.](dc161541f1){#F1}

###### 

Hazard ratio (95% CI) of incident diabetes by major diabetes risk factor groups stratified by hs-cTnT

                         ≤5 ng/L     6--8 ng/L           9--13 ng/L          ≥14 ng/L            *P* for trend   *P* for interaction[\*](#t2n1){ref-type="table-fn"}
  ---------------------- ----------- ------------------- ------------------- ------------------- --------------- -----------------------------------------------------
  Overall                                                                                                        
   Model 1               Reference   1.09 (0.97--1.23)   1.35 (1.16--1.56)   1.66 (1.36--2.02)   \<0.001         --
   Model 2               Reference   0.98 (0.86--1.11)   1.14 (0.99--1.33)   1.25 (1.03--1.53)   0.018           --
   Model 3               Reference   0.93 (0.82--1.05)   1.12 (0.96--1.30)   1.13 (0.93--1.38)   0.154           --
  Undiagnosed diabetes                                                                                           
   Model 1               Reference   0.95 (0.72--1.24)   1.03 (0.74--1.43)   0.86 (0.59--1.24)   0.538           --
   Model 2               Reference   0.94 (0.71--1.25)   1.13 (0.79--1.62)   0.84 (0.57--1.23)   0.615           --
   Model 3               Reference   0.87 (0.66--1.16)   1.09 (0.77--1.55)   0.81 (0.55--1.19)   0.485           --
  Fasting glucose                                                                                                
   Normal                                                                                                        
    Model 1              Reference   0.95 (0.73--1.23)   1.07 (0.75--1.51)   2.13 (1.44--3.15)   0.014           \<0.001
    Model 2              Reference   0.91 (0.70--1.19)   1.02 (0.72--1.44)   1.81 (1.22--2.70)   0.078           \<0.001
    Model 3              Reference   0.91 (0.70--1.19)   1.02 (0.72--1.45)   1.82 (1.22--2.71)   0.072           0.012
   Impaired                                                                                                      
    Model 1              Reference   1.03 (0.88--1.21)   1.33 (1.10--1.61)   1.21 (0.90--1.62)   0.009           --
    Model 2              Reference   0.93 (0.79--1.10)   1.15 (0.95--1.39)   0.96 (0.71--1.29)   0.578           --
    Model 3              Reference   0.94 (0.79--1.10)   1.12 (0.93--1.36)   0.96 (0.72--1.29)   0.661           --
  Metabolic syndrome                                                                                             
   No                                                                                                            
    Model 1              Reference   0.97 (0.79--1.20)   1.07 (0.82--1.40)   1.70 (1.23--2.37)   0.027           \<0.001
    Model 2              Reference   0.91 (0.74--1.12)   1.00 (0.76--1.31)   1.54 (1.10--2.15)   0.150           \<0.001
    Model 3              Reference   0.80 (0.65--1.00)   0.95 (0.72--1.25)   1.47 (1.05--2.05)   0.408           \<0.001
   Yes                                                                                                           
    Model 1              Reference   1.08 (0.93--1.26)   1.34 (1.12--1.60)   1.39 (1.09--1.77)   \<0.001         --
    Model 2              Reference   1.01 (0.87--1.18)   1.21 (1.01--1.45)   1.18 (0.92--1.51)   0.043           --
    Model 3              Reference   0.96 (0.82--1.12)   1.18 (0.98--1.41)   1.03 (0.80--1.32)   0.280           --

Model 1: age, race-center, sex; model 2: model 1 plus total cholesterol, LDL-C, HDL-C, triglycerides, cholesterol-lowering medication use, BMI, systolic blood pressure, blood pressure--lowering medication use, smoking status, eGFR, family history of coronary heart disease, waist circumference, physical activity, education level, and annual family income level; model 3: model 2 plus fasting glucose.

\**P* value for interaction within the respective subgroup, where applicable.

To examine the continuous association, we modeled hs-cTnT as a piece-wise linear spline with knots at 5, 8, and 14 ng/L using a fully adjusted model that included fasting glucose. There was a nonsignificant increase in the risk for incident diagnosed diabetes for participants with hs-cTnT \<8 ng/L, but the risk appeared to sharply increase among participants with hs-cTnT between 8 and 14 ng/L. Participants with hs-cTnT ≥14 ng/L had a statistically significant elevation in risk for diagnosed diabetes with an HR \>1.2, although the incremental increase in risk with further rise in hs-cTnT beyond 14 ng/L was small ([Fig. 2](#F2){ref-type="fig"}).

![Adjusted HR and 95% CI of incident diabetes by hs-cTnT level with superimposed frequency histograms. *A*: The linear spline model has three knots at 5, 8, and 14 ng/L. *B*: The linear spline model has one knot at 6 ng/L. The hs-cTnT level is represented by solid lines and the 95% CI is represented by the shaded area. The data were truncated at the 99th percentiles. The models were adjusted for age, race-center, sex, total cholesterol, HDL-C, LDL-C, triglycerides, BMI, eGFR, systolic blood pressure, blood pressure--lowering medication use, smoking status, cholesterol-lowering medication use, and fasting glucose.](dc161541f2){#F2}

A higher risk for diagnosed diabetes among participants with hs-cTnT ≥14 ng/L was also observed in subgroup analysis for participants not taking statins (HR 1.34; 95% CI 1.09--1.66), those without hypertension (HR 1.71; 95% CI 1.22--2.41), and those without self-reported hypercholesterolemia (HR 1.33; 95% CI 1.07--1.64) ([Table 3](#T3){ref-type="table"}). After adjustment for glucose, these relationships remained significant only for those without hypertension (HR 1.46; 95% CI 1.03--2.07), and overall, the interaction term among the subgroups was statistically nonsignificant.

###### 

Subgroup analysis of the HR (95% CI) for incident diabetes by hs-cTnT group

                         ≤5 ng/L     6--8 ng/L           9--13 ng/L          ≥14 ng/L            *P* for trend   *P* for interaction[\*](#t3n1){ref-type="table-fn"}
  ---------------------- ----------- ------------------- ------------------- ------------------- --------------- -----------------------------------------------------
  Sex                                                                                                            
   Men                                                                                                           
    Model 1              Reference   0.94 (0.79--1.13)   1.03 (0.84--1.27)   1.30 (1.02--1.65)   0.088           0.148
    Model 2              Reference   0.91 (0.76--1.09)   1.06 (0.87--1.30)   1.20 (0.94--1.54)   0.156           0.172
   Women                                                                                                         
    Model 1              Reference   0.99 (0.83--1.18)   1.27 (1.01--1.59)   0.88 (0.57--1.35)   0.367           --
    Model 2              Reference   0.93 (0.78--1.11)   1.20 (0.96--1.50)   0.79 (0.51--1.22)   0.930           --
  Race                                                                                                           
   White                                                                                                         
    Model 1              Reference   0.94 (0.81--1.08)   1.14 (0.96--1.36)   1.20 (0.95--1.51)   0.096           0.393
    Model 2              Reference   0.90 (0.77--1.04)   1.05 (0.89--1.26)   1.12 (0.88--1.42)   0.458           0.364
   Black                                                                                                         
    Model 1              Reference   1.05 (0.82--1.33)   1.08 (0.80--1.46)   1.25 (0.85--1.83)   0.289           --
    Model 2              Reference   0.98 (0.77--1.25)   1.13 (0.83--1.52)   1.10 (0.75--1.61)   0.483           --
  Age                                                                                                            
   \<65 years                                                                                                    
    Model 1              Reference   1.00 (0.86--1.18)   1.32 (1.09--1.62)   1.21 (0.91--1.62)   0.018           0.202
    Model 2              Reference   0.94 (0.80--1.10)   1.34 (1.10--1.64)   1.22 (0.91--1.62)   0.025           0.132
   ≥65 years                                                                                                     
    Model 1              Reference   0.96 (0.78--1.17)   0.99 (0.79--1.23)   1.26 (0.95--1.67)   0.311           --
    Model 2              Reference   0.92 (0.76--1.13)   0.92 (0.73--1.15)   0.99 (0.74--1.32)   0.645           --
  Statin use                                                                                                     
   Yes                                                                                                           
    Model 1              Reference   0.64 (0.42--0.97)   1.15 (0.76--1.72)   0.63 (0.31--1.25)   0.495           0.174
    Model 2              Reference   0.73 (0.48--1.11)   1.13 (0.76--1.70)   0.78 (0.39--1.55)   0.817           0.228
   No                                                                                                            
    Model 1              Reference   1.03 (0.91--1.17)   1.14 (0.97--1.34)   1.34 (1.09--1.66)   0.006           --
    Model 2              Reference   0.97 (0.85--1.11)   1.13 (0.96--1.32)   1.20 (0.97--1.48)   0.069           --
  Hypercholesterolemia                                                                                           
   Yes                                                                                                           
    Model 1              Reference   0.64 (0.44--0.92)   1.10 (0.77--1.57)   0.81 (0.44--1.47)   0.656           0.046
    Model 2              Reference   0.71 (0.50--1.03)   0.98 (0.69--1.40)   0.97 (0.53--1.76)   0.689           0.104
   No                                                                                                            
    Model 1              Reference   1.05 (0.92--1.20)   1.14 (0.97--1.34)   1.33 (1.07--1.64)   0.008           --
    Model 2              Reference   0.99 (0.86--1.13)   1.13 (0.95--1.33)   1.18 (0.95--1.46)   0.085           --
  Hypertension                                                                                                   
   Yes                                                                                                           
    Model 1              Reference   1.01 (0.86--1.19)   1.17 (0.97--1.41)   1.08 (0.85--1.38)   0.190           0.116
    Model 2              Reference   0.95 (0.81--1.12)   1.13 (0.94--1.36)   1.00 (0.78--1.29)   0.523           0.387
   No                                                                                                            
    Model 1              Reference   0.92 (0.75--1.12)   1.05 (0.81--1.36)   1.71 (1.22--2.41)   0.071           --
    Model 2              Reference   0.88 (0.72--1.07)   1.08 (0.83--1.39)   1.46 (1.03--2.07)   0.199           --
  BMI                                                                                                            
   \<25 kg/m^2^                                                                                                  
    Model 1              Reference   0.87 (0.61--1.22)   0.89 (0.55--1.45)   0.97 (0.48--1.99)   0.579           \<0.001
    Model 2              Reference   0.83 (0.59--1.18)   0.89 (0.54--1.45)   0.89 (0.43--1.84)   0.449           \<0.001
   25--30 kg/m^2^                                                                                                
    Model 1              Reference   1.14 (0.93--1.40)   1.15 (0.89--1.48)   1.46 (1.04--2.05)   0.032           --
    Model 2              Reference   1.08 (0.88--1.33)   1.07 (0.83--1.39)   1.41 (1.00--1.98)   0.097           --
   ≥30 kg/m^2^                                                                                                   
    Model 1              Reference   0.94 (0.79--1.12)   1.21 (0.99--1.48)   1.19 (0.91--1.55)   0.082           --
    Model 2              Reference   0.89 (0.74--1.06)   1.21 (0.99--1.48)   1.03 (0.78--1.34)   0.337           --

Model 1: age, race-center, sex, total cholesterol, HDL-C, LDL-C, triglycerides, BMI, eGFR, systolic blood pressure, blood pressure--lowering medication use, smoking status, cholesterol-lowering medication use, family history of coronary heart disease, waist circumference, physical activity, education level, and annual family income level; model 2: model 1 plus fasting glucose.

\**P* value for interaction within the respective subgroup, where applicable.

Adding hs-cTnT to a model that contained age, race, and sex improved the C statistic for the prediction of diabetes by +0.0089 (*P* \< 0.001) ([Table 4](#T4){ref-type="table"}). In the fully adjusted model with fasting glucose, there was a C statistic of 0.7636, indicating good prediction. The addition of hs-cTnT to this fully adjusted model that already included fasting glucose also demonstrated a statistically significant increase in the C statistic (+0.0008, *P* = 0.023). The addition of hs-cTnT provided a similar improvement in the C statistic of 0.0006 (*P* = 0.04) among individuals at low risk for diagnosed diabetes and CVD (those without hypertension, hypercholesterolemia, or impaired fasting glucose) and an improvement of 0.005 (*P* = 0.005) for those with normal fasting glucose ([Table 4](#T4){ref-type="table"} and [Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1541/-/DC1)). The NRI and integrated discrimination improvement index analyses were largely consistent with the C-statistic results, demonstrating that hs-cTnT was associated with the largest improvement in risk discrimination for participants in the "low-risk" group or those with normal fasting glucose, although these improvements were not statistically significant for the continuous NRI ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1541/-/DC1)).

###### 

Risk prediction for incident diabetes

                                                    C statistic   Change in C statistic[\*\*](#t4n2){ref-type="table-fn"}   *P* value[\*\*](#t4n2){ref-type="table-fn"}
  ------------------------------------------------- ------------- --------------------------------------------------------- ---------------------------------------------
  Overall                                                                                                                   
   Age, sex, race                                   0.5749        Reference                                                 Reference
    +Risk factors[\*](#t4n1){ref-type="table-fn"}   0.6983        0.1235                                                    \<0.001
    +Fasting glucose                                0.7438        0.1690                                                    \<0.001
    +hs-cTnT                                        0.5838        0.0089                                                    \<0.001
   Fully adjusted without hs-cTnT                   0.7636        0.1888                                                    \<0.001
   Fully adjusted with hs-cTnT                      0.7644        0.1896                                                    0.023[†](#t4n3){ref-type="table-fn"}
  Low-risk group[^a^](#t4n4){ref-type="table-fn"}                                                                           
   Age, sex, race                                   0.5690        Reference                                                 Reference
    +Risk factors[\*](#t4n1){ref-type="table-fn"}   0.6961        0.1271                                                    \<0.001
    +Fasting glucose                                0.7463        0.1774                                                    \<0.001
    +hs-cTnT                                        0.5772        0.0083                                                    \<0.001
   Fully adjusted without hs-cTnT                   0.7658        0.1968                                                    \<0.001
   Fully adjusted with hs-cTnT                      0.7664        0.1975                                                    0.040[†](#t4n3){ref-type="table-fn"}
  Normal fasting glucose                                                                                                    
   Age, sex, race                                   0.5615        Reference                                                 Reference
    +Risk factors[\*](#t4n1){ref-type="table-fn"}   0.6871        0.1256                                                    \<0.001
    +Fasting glucose                                0.7435        0.1820                                                    \<0.001
    +hs-cTnT                                        0.5766        0.0151                                                    \<0.001
   Fully adjusted without hs-cTnT                   0.7258        0.1642                                                    \<0.001
   Fully adjusted with hs-cTnT                      0.7308        0.1693                                                    \<0.001[†](#t4n3){ref-type="table-fn"}

\*Models adjusted for: age, race-center, sex, total cholesterol, HDL-C, LDL-C, triglycerides, BMI, eGFR, systolic blood pressure, blood pressure--lowering medication use, smoking status, cholesterol-lowering medication use, family history of coronary heart disease, waist circumference, physical activity, education level, and annual family income level.

\*\*Compared with age, sex, and race, except where noted.

†Compared with the fully adjusted model without hs-cTnT.

^a^Defined as no hypertension, hypercholesterolemia, or metabolic syndrome.

Censoring of the first 2 years and first 5 years of follow-up showed similar results to our analysis for complete follow-up, although the overall results were more attenuated with censoring of the first 5 years of follow-up ([Supplementary Tables 3 and 4](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1541/-/DC1)). Additional adjustment for alcohol consumption, parental history of diabetes, and insulin levels did not appreciably alter our results ([Supplementary Table 5](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1541/-/DC1)).

Conclusions {#s9}
===========

Our results show that among participants without clinically diagnosed CVD, the presence of subclinical myocardial damage---determined by an elevation in hs-cTnT---was associated with a modest but statistically significantly increased risk of incident diagnosed diabetes. This association was strongest among participants without a traditional risk factor and among those at low risk for incident diagnosed diabetes and CVD. Detectable levels of hs-cTnT may potentially be a result of an individual or a combination of myocardial insults because it is associated with submyocardial infarction, underlying structural myocardial disease such as left ventricular hypertrophy, heart failure, and microvascular disease ([@B19]--[@B22]). These findings suggest that hs-cTnT may incorporate overlapping pathophysiology for the development of both diabetes and CVD, which could help to prioritize prevention strategies for these individuals. Hyperglycemia is strongly associated with microvascular dysfunction and, along with lipotoxicity, has been suggested as a possible mechanism to explain elevated hs-cTnT levels and microvascular myocardial infarctions among individuals with diabetes ([@B23]). Other possible mechanisms include shared risk factors between diabetes and CVD that are not directly evaluated here, such as inflammation, endothelial dysfunction, and platelet activation. It may be that a certain amount of subclinical cardiovascular damage from early hyperglycemia (below the threshold for a diagnosis of diabetes) and/or coexisting CVD risk factors may accrue before the onset of diabetes ([@B24]). Therefore, an elevated hs-cTnT may at least partially serve as a marker of the cumulative long-term exposure to pathophysiologic changes that occur before diabetes is typically diagnosed. The statistically significant improvement in the C statistic beyond fasting glucose and other risk factors, although clinically small, demonstrates that hs-cTnT provides an additional description of the risk of diabetes not captured by traditional risk factors.

We found that even after adjustment for traditional diabetes risk factors, there was an increased risk of diagnosed diabetes among participants with elevated levels of hs-cTnT. Further adjustment for fasting glucose attenuated this relationship to null, which became statistically nonsignificant. However, the inclusion of fasting glucose as a covariable in our models may represent overadjustment, because fasting glucose also reflects underlying hyperglycemia and those individuals with the highest glucose levels are more likely to cross the threshold to incident diagnosed diabetes. Despite this, we found that the addition of hs-cTnT resulted in a statistically significant, although clinically modest, increase in the risk prediction of incident diagnosed diabetes when added to fully adjusted models that included fasting glucose. Moreover, we found that nearly two-thirds of participants who were subsequently diagnosed with diabetes had evidence of subclinical myocardial damage at baseline and that this percentage remained virtually unchanged after those with undiagnosed diabetes at baseline (20.1%) were excluded. Possible mechanisms for the shared development of diabetes and CVD include increased oxidative stress and advanced glycation end products, both of which have been suggested as pathways for β-cell damage and elevations in hs-cTnT ([@B25]--[@B29]).

Although our results demonstrate an overall association between hs-cTnT and incident diagnosed diabetes, they suggest that the relationship is stronger in certain groups of individuals. First, the relationship with incident diabetes was not significant at hs-cTnT levels \<8 ng/L and was relatively weak for levels \<14 ng/L. These levels of hs-cTnT are representative of subclinical myocardial damage, but other nonglucose risk factors may be responsible for most of the increase in hs-cTnT at these lower levels, which is suggested by the smaller attenuation in risk for diabetes after adjustment for glucose in these groups. Accordingly, these relatively low elevations of hs-cTnT may also reflect a lower cumulative exposure to hyperglycemia in which fewer individuals would be expected to progress to incident diagnosed diabetes.

Second, we found that the relative relationship between hs-cTnT and incident diagnosed diabetes was stronger for participants who would traditionally be considered at lower risk for diabetes and CVD such as those with normal fasting glucose, those without metabolic syndrome, those without cardiovascular risk factors, such as hypertension or hypercholesterolemia, those not treated with statin therapy, and those \<65 years old. Furthermore, the association between hs-cTnT and incident diagnosed diabetes remained significant even after adjusting for fasting glucose, with the exception of participants without hypertension, in which it became nonsignificant (*P* = 0.085). This stronger relationship in low-risk individuals with less attenuation from adjustment for fasting glucose suggests that there may be a treatment effect. Participants without these risk factors would not be identified as at increased risk for diabetes and/or CVD and, therefore, would be unlikely to be treated. However, individuals with risk factors would presumably be identified as at higher risk for diabetes and CVD and thus more likely to be prescribed treatment. Therefore, the treatment of risk factors may modify the relationship between hs-cTnT and incident diabetes, possibly resulting in a lower hs-cTnT for individuals at higher risk for incident diabetes. This is supported by evidence demonstrating that obesity, diabetes, and persistent elevations in hypertension are associated with increases in hs-cTnT during 6 years of follow-up, although further work is needed to confirm whether a reduction in risk factors is associated with a reduction in hs-cTnT ([@B30]).

These results demonstrate that individuals without traditional diabetes and CVD risk factors, such as impaired fasting glucose, hypercholesterolemia, or hypertension, who have a highly elevated hs-cTnT of ≥14 ng/L, are at an increased risk for incident diagnosed diabetes. Furthermore, despite the absence of these traditional diabetes and CVD risk factors, they are also at an increased risk for CVD and all-cause mortality by virtue of an elevated hs-cTnT ([Supplementary Table 6](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1541/-/DC1)) ([@B15],[@B31],[@B32]). This is especially relevant, because it has been suggested that one reason glucose-lowering trials have largely failed to show reductions in CVD is that the treatment is too late in the disease process after irreversible atherosclerotic damage has already occurred ([@B33]). Therefore, individuals with a low risk profile but a highly elevated hs-cTnT may benefit from closer monitoring with an increased emphasis on dietary and lifestyle modification. Furthermore, the addition of primary prevention medications, such as aspirin and statins, could be considered for patients with a highly elevated hs-cTnT who have a borderline ASCVD risk (5--7.5%) based on the Pooled Cohort equation. Identifying individuals with a highly elevated hs-cTnT who have an increased risk for both diabetes and CVD would also enable resources to be focused on those at highest risk for diabetes and the associated CVD complications.

Certain limitations of this study should be considered in the interpretation of our results, including the lack of follow-up blood glucose measurements and reliance on reports of diagnosed diabetes and glucose-lowering medication use during annual telephone calls to define incident diagnosed diabetes cases. This likely resulted in missing many undiagnosed cases during follow-up, especially early in follow-up. Indeed, the definition of incident diagnosed diabetes used in the current study (identified by self-report or use of a diabetes medication) has been shown to be specific (87%) but has a low sensitivity (59%) compared with a definition incorporating HbA~1c~ ≥6.5% ([@B34]). We used this definition of incident diabetes because there is no biochemical information after Visit 4 (the baseline for this analysis) in ARIC to define incident diabetes. We used only a single measurement of hs-cTnT and the other risk factors examined here, as understanding the prognostic relevance of single measurements is most applicable to clinical care.

We cannot rule out the possibility that reverse causation may explain our results. After adjustment, however, we found that the strongest association between hs-cTnT and incident diabetes was among individuals with normal fasting glucose. Indeed, among individuals with undiagnosed diabetes, no association was found between hs-cTnT and incident diabetes, even in models adjusted only for demographics. The results of subgroup analyses should be interpreted keeping in mind the multiple tests and relatively small sample size of certain subgroups. In addition, as with any observational study, residual confounding remains a concern.

Strengths of this study include the prospective long-term follow-up of more than a decade in participants from a community-based study. This study also benefited from the annual follow-up with participants, rigorous measurement of known diabetes and CVD risk factors, and the use of a centralized laboratory to standardize the analysis of the biomarkers.

Overall, these results demonstrate that individuals without CVD who have subclinical myocardial damage, as represented by an elevated hs-cTnT level, are more likely to develop diagnosed diabetes. Surprisingly, this relationship was strongest in participants who lacked a traditional risk factor or group of risk factors, which suggests that the treatment of traditional risk factors may modify the relationship between hs-cTnT and risk of incident diagnosed diabetes. Regardless, an elevated hs-cTnT is associated with both an increased risk of incident diagnosed diabetes and CVD. This may reflect a pathophysiologic overlap between CVD and diabetes incorporated by hs-cTnT, which is beyond that encompassed by fasting glucose and traditional risk factors. Accordingly, our results demonstrate that the measurement of hs-cTnT can identify individuals who are at an increased risk of both diagnosed diabetes and CVD, which may facilitate the use of resources for those at an increased risk for the associated complications of diabetes and CVD.
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======================

###### Supplementary Tables

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1541/-/DC1>.
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